Immune system function in the microgravity of space
Researchers from the School of Engineering and Applied Science and the Perelman School of Medicine are developing a technology to better understand how microgravity negatively affects immune system function.
There are exciting plans to push the frontiers of human space exploration, sending astronauts deeper into the solar system than ever before. But before achieving a better understanding of the mysteries of the universe, crucial mysteries about how the human body responds to space environments need to be investigated.
Researchers Dan Huh, a bioengineer in the School of Engineering and Applied Science, and G. Scott Worthen, a professor of pediatrics in the Perelman School of Medicine and a physician-scientist in neonatology at Children’s Hospital of Philadelphia, are developing a technology to better understand how microgravity—an environmental condition in which people and objects appear to be weightless—negatively affects immune system function.
Understanding this occurrence is particularly important in microgravity environments such as those in a spacecraft and the International Space Station (ISS), where pathogens such as viruses, bacteria, and fungi are known to be present.
Huh and Worthen were recently awarded a $2 million grant co-sponsored by NASA, the Center for the Advancement of Science in Space, and the National Center for Advancing Translational Sciences at the National Institutes of Health. The funds will allow the researchers to engineer microphysiological systems, better known as “tissues-on-a-chip,” that model the human airway and bone marrow. Eventually, they hope to combine the models to emulate and understand the integrated immune responses of the human respiratory system in microgravity.
These chips will be launched to the International Space Station aboard a SpaceX rocket—once in 2019 and again in 2021—to allow the researchers to see how the tissues respond to infections in the microgravity environment.
Huh has been working on this “tissue-on-a-chip” technology since it was first pioneered at Harvard. He and his team designed a microfluidic device in which they cultured lung and capillary cells on either side of a porous membrane and stretched them to mimic breathing in the lung.
For the space program, called “chips in space,” a team led by Huh and Worthen aims to model a condition called immunosuppression by developing an airway on a chip, sending it to the ISS and then infecting the airway tissue in microgravity to monitor what happens.
“It's been known since the early days of human space flight that astronauts and cosmonauts become more prone to infection during or right after space flight,” Huh says. “Studies have shown that the microgravity environment in space can alter various aspects of immune function in the human body. For example, the number and activity of immune cells have been shown to decrease in microgravity. This unique environment can also change the production of cytokines and the expression of genes and surface receptors that play a critical role in immune responses. Much remains to be learned about the underlying mechanisms of these undesirable changes.”
One component of the project, led by Worthen, is investigating neutrophils, a type of white blood cell. When infections occur in the lung, these neutrophils are mobilized from the bone marrow and travel through the bloodstream to invade the lung tissue and get to the site of infection. This is a critical process in human immune response to pathogens.
But there’s evidence that the mobilization of these cells actually becomes compromised in microgravity environments. The researchers’ ultimate goal is to develop a bone marrow on a chip and link it to the airway on a chip. They will then send the integrated system up to the ISS, infect the airway tissue and, in addition to collecting the samples from the airway tissue, look at the mobilization of neutrophils from the bone marrow on a chip to the airway on a chip.
“It's really exciting to think about the possibility of exploring the potential of organ-on-a-chip technology for space biology,” Huh says. “There are a lot of ambitious ideas and plans for space exploration. We already know that the immune system responds differently in the microgravity environment but little is known about why these responses are different. In the long term, we believe that these immunological deficits will be a critically important health issue and may also be an unavoidable problem as we start thinking about the journey beyond low Earth orbit into deep space. Our research in this project will be an important part of collective efforts to prepare ourselves for an exciting era of human space exploration.”
Dan Huh is the Wilf Family Term Assistant Professor of Bioengineering in the School of Engineering and Applied Science.
This article originally appeared in the Sept. 28, 2017 edition of the Penn Current Express.
When the Schuylkill swallowed the city: Lessons from Hurricane Ida’s historic flood
New Penn research shows that Hurricane Ida wasn’t a once-in-a-century anomaly but a preview of how climate change, urbanization, and aging infrastructure are rewriting flood risk.
The Fed explained: What it does and why it matters
Former Philadelphia Fed President Patrick Harker and financial historian Peter Conti-Brown, both Wharton professors, unpack the central bank’s origins, its unusual structure, and the quiet ways it shapes the economy
How population changes are impacting primary education worldwide
Research from Penn sociologist Emily Hannum and colleagues reveals regional trends in whether school-age populations are increasing, plateauing, or decreasing—and shows how different countries are responding.
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
Fighting oral cancer with bioengineered chewing gum
Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.
